downgrad neutral sotp valuat
move neutral remainco valn rebas
downgrad neutral base updat sotp valuat includ
expect dilut upjohn spin-merg revers morri trust valuat outlook
remainco concern post incl valuat pfe upjohn es come
disproportion loss profit total sotp valuat less sensit
newco valuat rebas pfizer remainco sale lower contribut margin
result remainco ep see remainco offer
attract growth profil skeptic share command pe
necessari remain buy rate new sotp valuat includ
pfe stake upjohn-myl remainco lower remainco sale
excl consum lower prevnar bavencio eucrisa pipelin
rebas upjohn prevnar xeljanz brand
conjunct upjohn-myl deal provid updat outlook revenu
impli downsid prior con updat combin compani sale
incl arri driven upjohn prevnar acip vote
expect weak xeljanz immunolog stem updat safeti label
upjohn revenu rebas super high margin unit may
factor will part upjohn multipl ebitda
ultim believ pfe decis spin-off upjohn unit make strateg sens
given unit like meaning drag growth allow compani
focu innov pharma unit howev stock work remainco
would need trade forward multipl ep view unlik given
current portfolio mix base estim pfizer remainco grow
sale compound-annual-growth-rate ep compound-annual-growth-rate repres one best near
medium growth profil major pharma view risk/reward balanc
forecast factor competit risk prevnar ipd vaccin allow
upsid ibranc adjuv indic probabl adjust
forecast rel mrk con cagr next
believ challeng premium multipl given patent cliff
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global biopharmaceut compani
diversifi portfolio product pipelin
candid one largest pharma
compani world measur market
capit revenu compon
jone industri averag compani
commerci oper bifurc two
busi segment innov ih
essenti eh gener
revenu total
follow spin-merg upjohn divis
think valuat benefit
upjohn divis come disproportion loss
profit rebas pfizer recomainco
sale lower contribut margin repres
lower ep estim see remainco
offer attract growth profil
skeptic share command signific pe
premium necessari remain buy rate
sg sale
 sale
tabl us eu major pharmaceut ep compound-annual-growth-rate vs valuat forward price-to-earnings
new po
updat valuat methodolog sotp driven ep estim reflect
new potenti structur follow merger-spr transact upjohn
price object po base part sotp analysi includ
remainco stake upjohn-myl
remainco assum compani trade multipl ep
remainco vs current averag us/eu pharma group previou
po base blend averag dcf wacc tgr
price object po base part sotp analysi includ
remainco stake upjohn-myl
remainco assum compani trade multipl ep
remainco vs current averag us/eu pharma group
risk sale downsid us sale continu declin and/or competit
take meaning market share ibranc could lead downsid estim
po inabl grow busi line forecast hold opex
spend flat level throughout forecast period transact
perceiv valu destruct
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
